• 1
    Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol.1988;139:461-469.
  • 2
    Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK; International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party; European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol.2011;29:2171-2177.
  • 3
    Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med.2003;349:859-866.
  • 4
    Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol.1992;10:1066-1073.
  • 5
    von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol.2000;18:3068-3077.
  • 6
    Dreicer R. The future of drug development in urothelial cancer. J Clin Oncol.2012;30:473-475.
  • 7
    Richter S, Sridhar SS. New directions for biologic targets in urothelial carcinoma. Mol Cancer Ther.2012;11:1226-1235.
  • 8
    Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The results database–update and key issues. N Engl J Med.2011;364:852-860.
  • 9
    Zarin DA, Tse T, Ide NC. Trial registration at between May and October 2005. N Engl J Med.2005;353:2779-2787.
  • 10
    Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem MA. Characteristics of clinical trials registered in, 2007-2010. JAMA.2012;307:1838-1847.
  • 11
    Morris MJ, Basch EM, Wilding G, et al. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer.2009;7:51-57.
  • 12
    Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJs. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther.2009;86:97-100.
  • 13
    National Cancer Institute. National Cancer Institute Fact Sheet: Cancer Research Funding. Accessed October 6,2012.